Navigation Links
New ability to regrow blood vessels holds promise for treatment of heart disease
Date:2/16/2012

University of Texas at Austin researchers have demonstrated a new and more effective method for regrowing blood vessels in the heart and limbs a research advancement that could have major implications for how we treat heart disease, the leading cause of death in the Western world.

The treatment method developed by Cockrell School of Engineering Assistant Professor Aaron Baker could allow doctors to bypass surgery and instead repair damaged blood vessels simply by injecting a lipid-incased substance into a patient. Once inside the body, the substance stimulates cell growth and spurs the growth of new blood vessels from pre-existing ones.

The method has been tested successfully on rats, and findings of the study were published recently in the Proceedings of the National Academy of Sciences.

"Others have tried using growth factors to stimulate vessel growth in clinical trials and have not been successful," said Baker, a faculty member in the school's Department of Biomedical Engineering. "We think that a major reason for this is that previous methods assumed the diseased tissues retained the ability to respond to a growth stimulus. Our method basically delivers extra components that can restore growth factor responsiveness to the tissue of patients with long-standing clinical disease."

The ability to regrow blood vessels could prove crucial to treating chronic myocardial ischemia disease, which affects up to 27 million patients in the U.S. and leads to a reduction of blood flow in the heart and lower limbs ultimately, causing organ dysfunction and failure.

Central ischemia, which effects the heart, occurs when the coronary vessels that feed blood to the heart become blocked or narrow due to a buildup of fatty deposits, or plaques. Such plaques are typically the result of a prolonged unhealthy diet or smoking, and factors like age, high blood pressure and diabetes increase the risks of the disease, Baker said.

Doctors have typically treated ischemia by physically opening the closed artery with a stent or surgically rerouting blood flow to the poorly perfused tissue. Both methods have limitations, however, and are not effective long-term.

The new method introduced by Baker and his research team builds off of a promising revascularization approach that, up until now, has shown limited efficacy in clinical trials for treating human disease.

The method combines a growth factor a substance capable of stimulating cellular growth, proliferation and cellular differentiation, as well as healing wounds known as fibroblast growth factor 2 (FGF-2) with a lipid-embedded receptor to enhance its activity.

A challenge for scientists and engineers, however, has been getting FGF-2 to bind with cell receptors the very molecules often found on the surface of the cell that receive chemical signals and direct activity in the cell from outside sources.

To overcome this, Baker's method embeds the growth factors in synthetic lipid-based nanoparticles containing a coreceptor known as syndecan-4. The nanoparticles containing co-receptors that, when delivered with the growth factor, enable improved cell binding so that the growth factor can direct the targeted cell to divide, proliferate and form new cells for tissue regrowth.

The incased substance was injected into rats with hindlimb ischemia and stimulated a complete recovery from the ischemia in just seven days.

"We hope this research will increase our understanding of how tissues become resistant to revascularization therapies and may lead to more effective treatments for this widespread and debilitating disease," said Baker, who was recognized last year with the National Institutes of Health Director's New Innovator Award.

Designed to support unusually creative new investigators with highly innovative research ideas at an early stage of their career, the award provides Baker with $1.5 million over five years to study and develop ways to regrow small blood vessels. With it, Baker is studying why previous attempts to restore blood flow to the heart have not been effective. His research aims to design new molecular tools and drug delivery methods to enable blood vessel growth in patients with diseases such as diabetes.


'/>"/>
Contact: Melissa Mixon
melissa.mixon@austin.utexas.edu
512-471-2129
University of Texas at Austin
Source:Eurekalert

Related biology news :

1. Study looks at possible link to hyper-excitability factors in epilepsy, autism and more
2. Sustainability, college athletics dont always connect
3. Diet, nutrient levels linked to cognitive ability, brain shrinkage
4. Slow road to stability for emulsions
5. Study of Yellowstone wolves improves ability to predict their responses to environmental changes
6. New materials capability to increase weapons explosive force demonstrated at Navy test range
7. NJIT professor plans 2012 sustainability workshop in Canada
8. Is sustainability science really a science?
9. After 25 years, sustainability is a growing science thats here to stay
10. Study details links between climate, groundwater availability - will help states prepare for drought
11. Bats show ability to change their ear shapes, making their hearing more flexible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... 2, 2016   Parabon NanoLabs (Parabon) ... Army Research Office and the Defense Forensics and ... of the company,s Snapshot Kinship Inference ... more generally, defense-related DNA forensics.  Although Snapshot is ... appearance and ancestry from DNA evidence), it also ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... ... SPIE Photonics West conference in San Francisco’s Moscone Center from February 16-18, ... same venue. , These latest InGaAs PIN diode standard packages feature a TO-46 ...
(Date:2/10/2016)... ... 10, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) and its affiliate Global Medical Training Network ... adipose and bone marrow therapies. , Through the new collaboration, Global Stem ...
(Date:2/9/2016)... N.J. , Feb. 9, 2016  Regenicin, ... biotechnology company specializing in the development and commercialization ... of damaged tissues and organs, recently reported the ... the first quarter of 2016. Lonza ... the new 2015 fiscal year in the process ...
Breaking Biology Technology: